Beyond Small Molecule Drug Discovery
RaQualia Pharma prides itself on its expertise in small molecule drug discovery, particularly emphasizing ion channels and G protein-coupled receptors (GPCRs). While we continue in refining and enhancing our existing technologies and expertise, we also embrace new drug discovery technologies and innovative ideas. This approach empowers us to pioneer new research and development, leading to the development of revolutionary medications.
RaQualia Pharma manages a proprietary drug discovery platform that seamlessly integrates compound design, synthesis, and comprehensive evaluation to attain remarkable efficiency at every stage. Our platform features sophisticated automated synthesis and purification systems, with the capacity to produce over 200 compounds weekly. This production capability, combined with our swift and thorough screening process, significantly accelerates our small molecule drug discovery initiatives. Additionally, our deep expertise and advanced electrophysiological evaluation techniques are vital for the development of ion channel-targeting drugs. This robust technology infrastructure lays a solid foundation for the success and efficiency of our asmall molecule drug discovery projects.
Comprehensive platform technologies are available for small molecule drug discovery.
Ion channels are key membrane proteins that act as "gates," that selectively permeate the passage of specific ions. These channels are localized in the cell membranes throughout the body. Permeation of ions into and out of cells through ion channels leads to a variety of physiological phenomena.
Electrochemical signals play a crucial role in several physiological phenomena, including neurotransmission, muscle contraction, hormone secretion, and cell proliferation and infiltration. Functional abnormalities or dysfunctions of ion channels are known to trigger diseases or pathological conditions. As a result, ion channels are regarded as critical drug targets for pharmaceuticals.
Despite their importance, ion channel-targeting drugs account for only about 5% of all pharmaceuticals, illustrating the significant challenges in developing these therapies. The hurdles stem from the complexities of evaluating electrochemical signals within living organisms and designing compounds that achieve high target selectivity to minimize adverse effects. Addressing these challenges necessitate the development of advanced drug discovery technologies.
From Pain and Gastrointestinal Diseases to Neurological Disorders, Cancer, and Genetic Disorders
RaQualia Pharma stands out for its cutting-edge technologies and innovative methodologies, incorporating electrophysiological evaluations led by highly skilled biologists, as well as sophisticated compound design and synthesis performed by expert medicinal chemists. This expertise has allowed us to make significant progress in the field of small molecule drug discovery, with a specific emphasis on "ion channel drug discovery." In the field of gastrointestinal diseases, our compounds have not only undergone successful clinical development but have also been launched as new medications, now accessible to patients globally.
Given their involvement in a wide range of physiological processes, ion channels offer extensive opportunities for drug discovery across various disease categories. Building on our considerable experience in ion channel drug discovery, we are extending our research from our original focus on pain and gastrointestinal diseases to encompass neurological disorders and cancer. Additionally, by embracing open innovation to incorporate new insights and technologies from external collaborations, we can initiate projects with a higher likelihood of success, including those that target genetic disorders. This strategy enables us to address the demand for innovative pharmaceuticals in areas with significant unmet medical needs.
Expanding Disease Areas on Ion Channel Drug Discovery
To swiftly apply new insights and technologies to drug discovery, we promote synergistic co-creation with partners.